Tokio Marine Asset Management Co. Ltd. Has $4.17 Million Holdings in Abbott Laboratories (NYSE:ABT)

Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,904 shares of the healthcare product maker’s stock after purchasing an additional 1,904 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Abbott Laboratories were worth $4,172,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Rise Advisors LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at approximately $37,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $40,000. Cornerstone Planning Group LLC boosted its holdings in shares of Abbott Laboratories by 79.4% in the third quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after buying an additional 201 shares during the period. Legacy Financial Group LLC acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $46,000. Finally, Briaud Financial Planning Inc acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $48,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now directly owns 18,760 shares in the company, valued at $2,223,060. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the sale, the executive vice president now owns 78,704 shares in the company, valued at $9,444,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the sale, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,435 shares of company stock worth $6,451,298. 0.47% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABT. Raymond James reissued a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research report on Wednesday. Barclays reduced their price objective on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday. Evercore ISI upped their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Citigroup upped their target price on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada cut their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research report on Thursday, April 18th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $121.50.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT traded down $0.70 during mid-day trading on Wednesday, reaching $106.89. 5,050,066 shares of the company traded hands, compared to its average volume of 5,719,627. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The firm has a market cap of $185.47 billion, a PE ratio of 33.30, a PEG ratio of 2.58 and a beta of 0.74. The company’s 50 day moving average price is $113.90 and its 200-day moving average price is $107.97.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The company had revenue of $9.96 billion for the quarter, compared to analyst estimates of $9.88 billion. During the same quarter in the prior year, the firm posted $1.03 EPS. Abbott Laboratories’s quarterly revenue was up 2.2% compared to the same quarter last year. On average, equities analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.06%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s payout ratio is currently 68.54%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.